QOL Maintained With Giredestrant Combo in Advanced BC

Published Date: 13 May 2026

Giredestrant plus everolimus does not increase treatment burden in advanced breast cancer, new safety and patient-reported outcome data from the evERA BC trial show.

Read Full News

Latest News

FDA Approves Novel Targeted Therapy for Rare Blood Cancer

The CD123-directed antibody and alkylating agent conjugate led to complete remission or clinical complete remission in nearly 70% of treatment-naive patients in a single arm study.

Durvalumab Plus BCG Earns FDA Nod for Bladder Cancer

The combination therapy is approved for BCG-naive patients with high-risk non-muscle-invasive disease.

Can Fasting Around Chemo Improve Ovarian Cancer Outcomes?

Women with ovarian cancer who fast shortly before and after chemotherapy have lower insulin levels, stronger tumor responses, and longer progression-free survival in a small randomized trial.

EMA Backs Breast Cancer SERD After FDA No Vote

The recommendation follows phase 3 data showing longer progression-free survival when patients switched to camizestrant plus a CDK4/6 inhibitor.

Datopotamab Deruxtecan Earns New Breast Cancer Indication

The antibody drug conjugate was approved by the FDA for certain patients with triple-negative breast cancer.

NP-Led Outreach Ups Cancer Screening in Rural Women Veterans

A nurse practitioner-led outreach program improves the rates of breast and cervical cancer screening among women veterans in rural areas, a retrospective study shows.

Todays Updates

Sandoz Files European Complaint About Chinese Antibiotic Imports

Swiss generic drugmaker Sandoz filed a draft ⁠anti-dumping complaint with the European Commission over Chinese imports ⁠of the antibiotic ingredient amoxicillin.

Fact vs. Fallacy: Challenging the Norms of Cancer Care

Dr Bishal Gyawali explores why lowering the bar for drug approvals is a fallacy and why asking for better evidence is a sign of patient advocacy, not an attack on innovation.

T2* MRI Maps Iron in Finger Soft Tissue in Microvasculopathy

Quantitative T2* MRI is feasible and reproducible for detecting microvasculopathy-related iron deposition in the soft tissues of the fingers.

Femoral BMD May Reflect Broader Health in Older Women

An observational study suggests that bone mineral density may serve as a marker of systemic health.

Eye Inflammation Tied to Anti-Adalimumab Antibody Formation

Patients with autoimmune diseases who experience ocular inflammation while on adalimumab have an increased risk of developing antibodies against the drug, according to a recent retrospective study.

WHO Identifies Ebola Treatments & Vaccines for Testing

The World Health Organization has recommended prioritizing three experimental treatments for the Bundibugyo strain of Ebola.

Natural Supplements Linked to Cases of Severe Liver Injury

Experts warn that concentrated herbal and dietary supplements are increasingly linked to severe liver injury, while regulation remains limited.

Todays Updates

Sandoz Files European Complaint About Chinese Antibiotic Imports

Swiss generic drugmaker Sandoz filed a draft ⁠anti-dumping complaint with the European Commission over Chinese imports ⁠of the antibiotic ingredient amoxicillin.

Fact vs. Fallacy: Challenging the Norms of Cancer Care

Dr Bishal Gyawali explores why lowering the bar for drug approvals is a fallacy and why asking for better evidence is a sign of patient advocacy, not an attack on innovation.

T2* MRI Maps Iron in Finger Soft Tissue in Microvasculopathy

Quantitative T2* MRI is feasible and reproducible for detecting microvasculopathy-related iron deposition in the soft tissues of the fingers.

Femoral BMD May Reflect Broader Health in Older Women

An observational study suggests that bone mineral density may serve as a marker of systemic health.

Eye Inflammation Tied to Anti-Adalimumab Antibody Formation

Patients with autoimmune diseases who experience ocular inflammation while on adalimumab have an increased risk of developing antibodies against the drug, according to a recent retrospective study.

WHO Identifies Ebola Treatments & Vaccines for Testing

The World Health Organization has recommended prioritizing three experimental treatments for the Bundibugyo strain of Ebola.

Natural Supplements Linked to Cases of Severe Liver Injury

Experts warn that concentrated herbal and dietary supplements are increasingly linked to severe liver injury, while regulation remains limited.

Latest News

The CD123-directed antibody and alkylating agent conjugate led to complete remission or clinical complete remission in nearly 70% of treatment-naive patients in a single arm study.

The combination therapy is approved for BCG-naive patients with high-risk non-muscle-invasive disease.

Women with ovarian cancer who fast shortly before and after chemotherapy have lower insulin levels, stronger tumor responses, and longer progression-free survival in a small randomized trial.

The recommendation follows phase 3 data showing longer progression-free survival when patients switched to camizestrant plus a CDK4/6 inhibitor.

The antibody drug conjugate was approved by the FDA for certain patients with triple-negative breast cancer.

A nurse practitioner-led outreach program improves the rates of breast and cervical cancer screening among women veterans in rural areas, a retrospective study shows.

News All Time

Only 1 in 4 Eligible Adults Receive Lung Screening

Complicated eligibility rules, stigma surrounding smoking and lung cancer, and confusion about the screening process continue to keep many high-risk patients from getting screened.

FDA Warns of Secondary Blood Cancer Risk With Tazverik

The FDA says the increased risk of hematologic secondary primary malignancies with tazemetostat now outweighs the benefits of the drug; Ipsen pulls it from the market.

FDA Approves Next-Gen Agent for Mantle Cell Lymphoma

The BCL-2 inhibitor was granted accelerated approval based on findings from the phase 1/2 BGB-11417-201 study.

No Survival Benefit Seen With Adjuvant Atezolizumab in TNBC

Triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy do not gain a survival benefit from adding atezolizumab to adjuvant capecitabine, shows trial.

When Healthcare Chatbots Fall Short of Human Connection

Researchers report that digital monitoring tools may improve symptom tracking, but nurses face added demands linked to alert verification and patient support.

Early PET May Help Tailor Therapy in Hodgkin Lymphoma

A trial evaluates whether very early FDG PET-guided treatment adaptation after one cycle of brentuximab vedotin-based chemotherapy improves outcomes in Hodgkin lymphoma.

PRO Data Strengthen Case for Dato-DXd in First-Line TNBC

Patients treated with datopotamab deruxtecan reported longer preservation of quality of life and physical functioning vs chemotherapy in metastatic TNBC.

FDA Advisors Split on Regimens for Breast, Prostate Cancers

The Oncologic Drugs Advisory Committee backed the prostate cancer drug but rejected a novel approach for breast cancer, highlighting challenges in defining clinical meaningfulness.

Combo Therapy Boosts Early CML Response but Not Long Term

A phase 3 trial evaluates the efficacy and safety of nilotinib with pegylated interferon alfa-2a in patients with newly diagnosed chronic-phase chronic myeloid leukemia.

De-escalation Misses the Mark in Inflammatory Breast Cancer

Amid a de-escalation trend in breast cancer treatment, less than one third of patients with inflammatory breast cancer receive guideline-endorsed trimodal therapy, despite survival benefits.

T-DXd Reduces Residual Disease in Early Breast Cancer

Neoadjuvant trastuzumab deruxtecan combination therapy reduces the residual cancer burden in high-risk early breast cancer, even if a pathologic complete response is not achieved, shows analysis.

Most NMIBC Recurrences Seen in BCG-Exposed Patients

A large real-world study examines outcomes and treatment patterns among patients with non-muscle-invasive bladder cancer treated with BCG.

Study Finds Microplastics Near Tumors; Experts Doubt Results

Using LDIR, O PTIR, Py GC/MS, and SEM, researchers quantified MNPs in 191 brain samples, but experts question the unusually high particle masses and urge methodological validation.

Liquid Biopsies Cut EBV Burkitt Lymphoma Time to Diagnosis

Broader implementation would require substantial investment, but long-term dividends of liquid biopsy analysis in the region could affect diagnosis and care of much more than just this cancer.

Can Exercise Extend Survival After Breast Cancer?

A ‘target trial’ emulation study suggests that regular exercise can help breast cancer survivors live longer.

PSA Screening Overdiagnosis Rises Sharply With Age

About one third of cancers detected by PSA screening at age 70, and more than half at age 80, are unlikely to become clinically meaningful within 15 years.

Recommended News For You

Study Finds Microplastics Near Tumors; Experts Doubt Results

Significant differences in breast cancer care still exist, but surgeons can change.

New policy review highlights the importance of health-related quality of life in advanced cancer

Chemotherapy Boosts Survival for Older Patients With TNBC

MRI can save rectal cancer patients from surgery, study suggests

New First-Line Option for Advanced ALK-Positive Lung Cancer

the contribution of cortactin to the development of cancer.

Recommended Articles For You

Multimodal Data Fusion with Deep Neural Networks - Revolutionizing Oncology with Precision Cancer Diagnosis 2025 

New Hope for Rectal Cancer Patients: Breakthrough Drug Shows Promising Results 

Unlocking the Potential of CPK Levels: How to Maximize Your Health Benefits 

Understanding Epoetin and Its Role in Treating Chronic Kidney Disease  

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

FDA OKs Subcutaneous Daratumumab Plus VRd for Myeloma

2.

Surgery may not be necessary to treat invasive breast cancer

3.

Radiation from CT scans could account for 5% of all cancer cases a year, study suggests

4.

FINAL USPSTF RECOMMENDATIONS ON ANXIETY, DEPRESSION, AND SUIICIDAL RISK.

5.

De-escalation Misses the Mark in Inflammatory Breast Cancer

1.

Can AI Become Our Oncologic Ally? A Look at Artificial Intelligence in Cancer Detection and Control

2.

A Closer Look at MCV Modules: Features, Functions, and Benefits 

3.

Understanding the Causes and Symptoms of Cavernous Sinus Thrombosis 

4.

Lactic Acid-Linked lncRNAs in Wilms Tumor: Decoding the Tumor Microenvironment & Prognosis

5.

How Prevident is Revolutionizing Oral Care

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- Further Discussion on A New Perspective

2.

Beyond the Mutation: Addressing the Unmet Needs in ALK-Positive NSCLC

3.

Navigating the Complexities of Ph Negative ALL - Part XVI

4.

Exploring Potentials of Lorlatinib: The Third Generation ALK-TKI Through CROWN Trial

5.

Understanding the Multifaceted Advantages of CDK4/6 Inhibitors in HR+/HER2- PALOMA 2 Study.

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot